The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Integr Cancer Ther. 2014 Mar;13(2):133-40. doi: 10.1177/1534735413510558. Epub 2013 Nov 25.
Pain control is an ongoing challenge in the oncology setting. Prior to implementing a large randomized trial at our institution, we investigated the feasibility, safety, and initial efficacy of acupuncture for uncontrolled pain among cancer patients.
Our hypotheses were that the acupuncture treatments provided would be ( : ) feasible, ( : ) safe, and ( : ) a beneficial adjunct to pain management.
This was a single arm, nonrandomized pragmatic pilot study.
Participants experiencing pain ≥4 on a 0 to 10 numeric rating scale received a maximum of 10 treatments on an individualized basis. Recruitment, attrition, compliance, and adverse events (AEs) were assessed. Pain (Brief Pain Inventory-Short Form), quality of life (MD Anderson Symptom Inventory [MDASI]), and patient satisfaction were assessed at baseline and at the end of treatment.
Of 115 patients screened, 52 (45%) were eligible and agreed to participate. Eleven (21%) were lost to follow-up, leaving 41 who completed all study procedures. No AEs were reported. Mean pain SEVERIT: was 6.0 ± 1.3 at baseline and 3.8 ± 2.0 at follow-up ( : < .0001). Pain INTERFERENC: was 6.2 ± 2.3 at baseline and 4.3 ± 2.8 at follow-up ( : < .0011). On the MDASI, the mean symptom SEVERIT: was 4.6 ± 1.8 at baseline and 3.2 ± 1.9 at follow-up ( : < .0001), and mean symptom INTERFERENC: was 5.8 ± 2.4 at baseline and 4.1 ± 2.9 at follow-up ( : < .002). Prescribed pain medications decreased across the course of the study. Patient satisfaction was high: 87% reported that their expectations were met "very well" or "extremely well"; 90% said they were likely to participate again; 95% said they were likely to recommend acupuncture to others; and 90% reported they found the service to be "useful" or "very useful."
Acupuncture was feasible, safe, and a helpful treatment adjunct for cancer patients experiencing uncontrolled pain in this study. Randomized placebo-controlled trials are needed to confirm these results.
在肿瘤学领域,疼痛控制一直是一个挑战。在我们机构实施大型随机试验之前,我们调查了针刺治疗癌症患者未控制疼痛的可行性、安全性和初步疗效。
我们的假设是提供的针刺治疗将是可行的、安全的,并且是疼痛管理的有益辅助手段。
这是一项单臂、非随机实用试验研究。
疼痛评分为 0 至 10 分的患者中,疼痛评分≥4 分的患者接受个体化的最多 10 次治疗。评估招募、流失、依从性和不良事件(AE)。在基线和治疗结束时评估疼痛(简短疼痛清单-简短形式)、生活质量(MD 安德森症状量表 [MDASI])和患者满意度。
在筛选的 115 名患者中,有 52 名(45%)符合条件并同意参加。11 名(21%)患者失访,41 名患者完成了所有研究程序。未报告任何不良事件。平均疼痛严重程度为 6.0 ± 1.3 分,随访时为 3.8 ± 2.0 分(: <.0001)。疼痛干扰为 6.2 ± 2.3 分,随访时为 4.3 ± 2.8 分(: <.0011)。在 MDASI 上,平均症状严重程度为 4.6 ± 1.8 分,随访时为 3.2 ± 1.9 分(: <.0001),平均症状干扰为 5.8 ± 2.4 分,随访时为 4.1 ± 2.9 分(: <.002)。研究过程中,规定的止痛药物用量减少。患者满意度高:87%的患者报告他们的期望“非常好”或“极好”得到满足;90%的患者表示他们可能再次参加;95%的患者表示他们可能会向他人推荐针灸;90%的患者表示他们发现该服务“有用”或“非常有用”。
在这项研究中,针刺对癌症患者未控制疼痛是可行的、安全的,并且是一种有益的辅助治疗方法。需要进行随机安慰剂对照试验来证实这些结果。